deltatrials

Obesity Trials in Katowice, Poland

Conditions / Obesity / Katowice, Poland

Obesity is a medical condition with active clinical research programs worldwide.

18 total trials for this combination

Showing top 10 of 18 trials

Trials

NCT ID Title Status Phase
NCT07037433 Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity RECRUITING
NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) ACTIVE_NOT_RECRUITING
NCT07037433 Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity RECRUITING
NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) ACTIVE_NOT_RECRUITING
NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) ACTIVE_NOT_RECRUITING
NCT05882045 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease ACTIVE_NOT_RECRUITING PHASE3
NCT06131372 A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo COMPLETED PHASE2
NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) ACTIVE_NOT_RECRUITING
NCT05929066 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight ACTIVE_NOT_RECRUITING PHASE3
NCT07037459 Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity RECRUITING

Related Pages